PROTAC Targeted Protein Degradation Therapy

PROTAC Targeted Protein Degradation Therapy

Introduction

Protac Targeted Protein Degradation Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox"> [@tomoshige2017]

| Property | Value | [@chirnomas2023]
|----------|-------| [@wang2022]
| Category | Experimental Therapy | [@takahashi2022]
| Target | Disease-causing proteins |
| Diseases | Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, ALS |
| Key Items | ARV-110, Molecular glues, AUTAC, LYTAC |
| Mechanism | Ubiquitin-proteasome system recruitment |

</div>

Overview

PROTAC Targeted Protein Degradation Therapy

Introduction

Protac Targeted Protein Degradation Therapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox"> [@tomoshige2017]

| Property | Value | [@chirnomas2023]
|----------|-------| [@wang2022]
| Category | Experimental Therapy | [@takahashi2022]
| Target | Disease-causing proteins |
| Diseases | Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, ALS |
| Key Items | ARV-110, Molecular glues, AUTAC, LYTAC |
| Mechanism | Ubiquitin-proteasome system recruitment |

</div>

Overview

PROTACs (Proteolysis-Targeting Chimeras) are bifunctional molecules that harness the cell's own [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) to selectively degrade disease-causing proteins. This represents a paradigm shift from traditional inhibition to actual elimination of target proteins. A single PROTAC molecule can degrade multiple target proteins through catalytic activity. ## Mechanism of Action

Molecular Glue Mechanism

PROTACs work through a three-step process:

• A target protein (e.g., mutant [huntingtin](/genes/htt), [tau](/proteins/tau), α-synuclein)
• An E3 ubiquitin ligase (cereblon, VHL, MDM2, cIAP1)

Key Advantages

• Catalytic activity: Substoichiometric dosing
• Undruggable targets: Can target proteins lacking active sites
• Temporal control: Protein levels reducible without complete knockout ## Disease-Specific Applications

Huntington's Disease

• HTTex1 (mutant huntingtin exon 1): Primary target
• B6H10 and Dheb compounds show efficacy in mouse models

Alzheimer's Disease

• [Tau](/proteins/tau) protein degradation: Multiple PROTACs in development
• [APP](/entities/app-protein) processing proteins: [BACE1](/entities/bace1) degraders
• [TDP-43](/proteins/tdp-43): For ALS/FTD

Parkinson's Disease

• [α-Synuclein](/proteins/alpha-synuclein): Direct targeting with small molecule PROTACs
• LRRK2: Kinase-independent degradation strategies

ALS

• SOD1 mutants: Promising preclinical results
• FUS: Under investigation ## Clinical Pipeline

Molecular Glues

• Smaller than traditional PROTACs
• Better pharmacokinetics
• Examples: thalidomide derivatives, indisulam

AUTAC (Autophagy-Targeting Chimeras)

• Target proteins for autophagic degradation
• Can degrade organelles and protein aggregates

LYTAC (Lysosome-Targeting Chimeras)

• Degrade extracellular and membrane proteins
• Use lysosomal trafficking receptors

Background

The study of Protac Targeted Protein Degradation Therapy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosome-neurodegeneration)
• [Huntington's Disease](/diseases/huntingtons)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

External Links

• [Arvinas PROTAC Platform](https://www.arvinas.com/)
• [PROTAC - Wikipedia](https://en.wikipedia.org/wiki/PROTAC)
• [Nature Reviews Drug Discovery - PROTACs](https://www.nature.com/articles/s41573-022-00574-5)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Palmitoylation-Targeted BACE1 Trafficking Disruptors](/hypothesis/h-441b25ba) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BACE1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1

Related Analyses:

• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;